A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
An Indian court has issued far-reaching directions to the government apparatus and pharma, among other stakeholders, as part of efforts to ensure patients suffering from rare diseases get timely access to treatments in the country.
The court order, which covers 105 petitions pertaining to the treatment of children suffering from rare diseases, touches upon funding, policy, regulatory and pricing aspects and captures the “arduous journey”...
Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.
The French drugmaker is expanding its neurology activities with the $470m deal.
Deal Snapshot: Orionis and Genentech signed a new partnership focused on molecular glues, on top of the one that they struck in 2023.
